Adrenocortical Carcinoma (ACC)

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    IGF-2 Overexpression 60–90 Cixutumumab (IGF-1R inhibitor):
    • Phase 1, with temsirolimus: Durable SD 40% (1)
    Linsitinib (IGF-1R inhibitor):
    • Phase 1: 1 PR and 4 SD out of 12 ACC pts (2,3)
    Figitumumab (IGF-1R inhibitor):
    • Phase 1: Short-term SD in 57% (4)
    EGFR Mutation/overexpression 4 Gefitinib (EGFR inhibitor):
    • Phase 2: RR 0% (5)
    Erlotinib (EGFR inhibitor):
    • Phase 2, with gemcitabine: RR 10% (6)
    BRAF Mutation 3 Sorafenib (VEGFR/RAF inhibitor):
    • Phase 2, with paclitaxel: RR % (7)
    Other topics in Targets by Organ Site